Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial

• Status: Completed
• Trial end date: 2008-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effects of low-dose aspirin for the primary prevention of vascular events in patients with type 2 diabetes in Japan.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kumamoto University
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Patients have type 2 diabetes mellitus (30 or more years old and 85 years old or less).

• Patients give their informed consent to participate.

Exclusion Criteria:

• Patient has electrocardiographic changes, including ischemic ST-segment depression, ST-segment elevation, or pathologic Q waves.

• Patient has fixed ischemic heart disease, utilizing coronary angiography.

• Patient has cerebral vascular disease, including cerebral infarction, past hemorrhage, and experience of transient ischemic attack.

• Patient has arteriosclerotic disease, which needs internal medicine and/or surgical medical treatment.

• Patient has already taken the following anti-platelet or anti-thrombotic medicine:

aspirin, ticlopidine, cilostazol, dipyridamole, trapidil, warfarin, and argatroban.

• Patient has severe gastric and/or duodenal ulcer.

• Patient has severe liver dysfunction.

• Patient has severe renal dysfunction.

• Patient has allergy for aspirin.

• Patient has atrial fibrillation.

• Pregnancy or the possible case of pregnancy.